Abstract:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current coronavirus disease 2019 (COVID-19) pandemic that has led to a global economic disruption and collapse. With several ongoing eﬀorts to develop vaccines and treatments for COVID-19, understanding the molecular interaction between the coronavirus, host cells, and the immune system is critical for eﬀective therapeutic interventions. Greater insight into these mechanisms will require the contribution and combination of multiple scientific disciplines including the techniques and strategies that have been successfully deployed by chemical biology to tease apart complex biological pathways. We highlight in this review well-established strategies and methods to study coronavirus–host biophysical interactions and discuss the impact chemical biology will have on understanding these interactions at the molecular level. 2 (ACE2) on alveolar cells, and establishment of upper respiratory tract infection via nose, eyes and mouth, the viral lifecycle proceeds with the fusion of viral envelope with cell membrane and subsequent release of viral RNA into the cell. The RNA is then translated to produce viral pre-proteins that are processed by its own proteases to release over two dozen eﬀector proteins which eventually participate in viral replication, hijacking of host pathways, and assembly of virions followed by release. or sub-genomic RNAs) are recognized by pattern recognition receptors such as Toll-like receptors (TLRs), retinoic- acid-inducible protein I (RIG-I), RIG-I like receptor, and melanoma differentiation-associated protein 5 (MDA-5) that recruit adapter mitochondrial antiviral-signaling protein (MAVS) and leads to activation of interferon regulatory factor 3 (IRF3) and NF- k B and the subsequent production of type I Interferons (IFNs) and pro-inflammatory cytokines ( e.g. IL-1 b and IL-6), respectively. Itaconate, an anti-inflammatory metabolite transported by TCA cycle intermediates ( e.g. citrate), results in activation of pathways involved in proinflammatory cytokines. Proinflammatory cytokines activate the mammalian target of rapamycin (mTOR) signaling in addition to the increased energy metabolism through aerobic glycolysis. The increased production of tricarboxylic acid cycle (TCA) intermediates e.g. succinate and citrate activate NF- k B downstream signaling resulting in the production of proin- flammatory cytokines. The antiviral activity of type I IFNs limit viral replication and modulate the innate and adaptive immune responses. They bind to interferon- a / b receptors (IFNARs), which are expressed on a number of different cells including macrophages and activate the JAK/STAT signaling pathway. This signaling leads to the formation of the STAT1/2/IRF9 complex and the induction of a plethora of IFN-stimulated genes (ISGs). Cytokines released by infected cells modulate the adaptive immune response by recruiting and activating immune cells such as macrophages, B-cells, and T-cells to orchestrate the elimination of the virus. However, an unbalanced immune response has been reported to cause hyper-inflammation, a condition termed as ‘cytokine storm’ in cases of severe clinical symptoms of COVID-19. Many, but not all, aspects of this model have been directly verified in the rapidly emerging SARS-CoV-2 experimental literature. characterize possible changes in the hijacked host protein function(s). Both IP-MS and AP-MS

Targeting Myeloid Differentiation Primary Response Protein 88 (MyD88) and Galectin-3 to Develop Broad-Spectrum Host-Mediated Therapeutics against SARS-CoV-2

Toll-Like Receptor Signaling in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Innate Immune Responses and the Potential Application Value of Toll-Like Receptor Immunomodulators in Patients with Coronavirus Disease 2019

Insight into the Emerging Role of SARS-CoV-2 Nonstructural and Accessory Proteins in Modulation of Multiple Mechanisms of Host Innate Defense.

MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity

Interferon-stimulated genes and their antiviral activity against SARS-CoV-2

Targeting the Ubiquitylation and ISGylation Machinery for the Treatment of COVID-19

Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past

SARS-CoV-2 ORF3a Protein as a Therapeutic Target against COVID-19 and Long-Term Post-Infection Effects

SARS‐CoV‐2 modulation of RIG‐I‐MAVS signaling: Potential mechanisms of impairment on host antiviral immunity and therapeutic approaches

The role of death domain proteins in host response upon SARS-CoV-2 infection: modulation of programmed cell death and translational applications

Inflammasomes during SARS-CoV-2 infection and development of their corresponding inhibitors

Targeting cytokine storm as the potential anti-viral therapy: Implications in regulating SARS-CoV-2 pathogenicity

Role of CCL2/CCR2 axis in the pathogenesis of COVID-19 and possible Treatments: All options on the Table

Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm

The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections

Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments

Therapeutic development targeting host heparan sulfate proteoglycan in SARS-CoV-2 infection

Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy

Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection

Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection

RSC Chemical Biology